• Entinostat-Keytruda Clinical Trial in NSCLC Will Proceed to Next Stage
  • ASTRO Issues Guidelines for Using High-dose Focused Radiation in Early-stage Lung Cancer
  • 70% of Patients with Brain Cancer Originating in the Lungs Responded to Tagrisso, Trial Shows
  • Keytruda Increases Survival of Lung Cancer Patients, Compared with Standard Chemo, Update Shows
  • Alecensa Doubles Time to Disease Progression in Untreated ALK+ NSCLC Patients Compared to Xalkori
  • Trilaciclib Improves Chemo’s Effectiveness Against Small Cell Lung Cancer, Study Finds
  • FDA Gives Green Light to Zykadia as First-line Therapy for ALK-positive NSCLC
  • EU Panel Recommends Approval of Zykadia as First-line Treatment for ALK-Positive NSCLC
  • Ventilation Holes in Cigarette Filters Have Increased Lung Cancer, Study Reports
  • Phase 3 Trial Shows Promising Results for Imfinzi in Subset of NSCLC Patients
  • Alunbrig Shows Promise in Certain Advanced NSCLC Patients with ALK Mutations, Study Reports
  • FDA Puts Keytruda on Accelerated Approval Track as Combo Lung Cancer Treatment